A5089570643- Statistical Methods in Clinical Trials
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Optimal Experimental Design Methods
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Advanced Causal Inference Techniques
- Endometrial and Cervical Cancer Treatments
- Pharmaceutical studies and practices
- PARP inhibition in cancer therapy
- Pancreatic and Hepatic Oncology Research
- PI3K/AKT/mTOR signaling in cancer
- Glioma Diagnosis and Treatment
- Meta-analysis and systematic reviews
- Computational Drug Discovery Methods
- COVID-19 and healthcare impacts
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Radiomics and Machine Learning in Medical Imaging
- Intraperitoneal and Appendiceal Malignancies
- Cancer Treatment and Pharmacology
Institut Curie
2015-2025
Centre de recherche en Epidémiologie et Santé des Populations
2016-2025
Inserm
2016-2025
Université Paris Sciences et Lettres
2023-2025
Université Paris-Saclay
2013-2025
Institut Gustave Roussy
2015-2024
Université de Versailles Saint-Quentin-en-Yvelines
2015-2024
ParisTech
2024
Université Paris-Sud
2015-2023
Université Paris Cité
2015-2022
Muscle-invasive bladder carcinoma (MIBC) constitutes a heterogeneous group of tumors with poor outcome. Molecular stratification MIBC may identify clinically relevant tumor subgroups and help to provide effective targeted therapies. From seven series large-scale transcriptomic data (383 tumors), we identified an subgroup accounting for 23.5% MIBC, associated shorter survival displaying basal-like phenotype, as shown by the expression epithelial basal cell markers. Basal-like presented...
Temporary circulatory support with extracorporeal membrane oxygenation (ECMO) is often the only alternative for supporting patients refractory cardiogenic shock (RCS). In practice, this strategy limited to a small minority of hospitalized in tertiary-care centres ECMO programs. The cardiac-RESCUE program was designed test feasibility providing distant from specialized centres, RCS remote locations.From January 2005 December 2009, hospitals without facilities throughout Greater Paris area...
This multicenter phase I study aimed to establish the recommended dose (RD) of epidermal growth factor receptor (EGFR) inhibitor erlotinib, given as monotherapy or with radiotherapy children malignant brain tumors. Group 1 included patients refractory relapsing tumors receiving erlotinib alone, and group 2 newly diagnosed brainstem gliomas erlotinib. A conventional 3 + escalation a continual reassessment method, respectively, were utilized in 4 levels: 75, 100, 125, 150 mg/m2 per day....
Purpose Phase I trials traditionally aim at determining the recommended phase II dose (RP2D) using grade ≥ 3 toxicity data from cycle 1 (C1) only. This design dates era of conventional chemotherapy and may not be relevant for new molecularly targeted agents (MTAs) usually administered in a chronic fashion which late or moderate toxicities deserve particular attention. Patients Methods All consecutive patients treated MTAs Royal Marsden Hospital Institut Gustave Roussy between January 2005...
Abstract Background Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics outcome diagnosed with during breast cancer treatment Institut Curie hospitals (ICH, Paris area, France). Methods An IRB-approved prospective registry was set up ICH on March 13, 2020, for all symptoms or radiologic signs. Registered data included patient history, tumor treatments, symptoms, radiological features, outcome. Data extraction done April...
Immune checkpoint inhibitors (ICIs) have been demonstrated to improve overall survival (OS) in several tumor types. Durable responses reported with these agents patients melanoma and lung cancer. We aimed quantify the proportion of who experience durable on ICIs compare it other drug classes.We retrieved published phase III randomized trials that included at least one ICI arm recurrent and/or metastatic setting. A response treatment was defined as a progression-free exceeded three times...
Objective: The mechanisms linking severe inflammation and coagulation during heatstroke are poorly understood. Here, we examined the roles of tissue factor pathway, leukocyte activation, mediators innate immunity in patients admitted to an intensive care unit for intense heat wave Paris. Design: Retrospective observational study. Setting: Intensive a university medical center. Patients: Eighteen critically ill with were enrolled study 14 age-matched sepsis as controls. Interventions: None....
The SHIVA trial is a multicentric randomised proof-of-concept phase II comparing molecularly targeted therapy based on tumour molecular profiling vs conventional in patients with any type of refractory cancer. Results the feasibility study first 100 enrolled are presented. Adult metastatic cancer who failed standard were eligible for study. profile was performed mandatory biopsy, and included mutations gene copy number alteration analyses using high-throughput technologies, as well...